Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Cannabidiol products to be regulated
CBD products for use in animals will now require marketing authorisation before they can be sold or supplied in the UK.
VMD contacting UK suppliers and manufacturers

The VMD has announced that veterinary products containing Cannabidiol (CBD) are veterinary medicines and should be regulated as such.

A veterinary medicine is defined in the Veterinary Medicines Regulations as:

“Any substance or combination of substances that may be used in, or administered to, animals with a view either to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.”

As such, the VMD says that CBD products for use in animals now require marketing authorisation before they can be sold or supplied in the UK.

There are currently no CBD products authorised in the UK for veterinary use. However, a veterinary surgeon may prescribe a legally obtained human CBD product under the provisions of the prescribing cascade.

‘Administration of an unauthorised product containing CBD without a veterinary prescription is an offence under Regulation 8 of the VMR,’ the VMD states. ‘Companies supplying CBD products for human use in line with the requirements of the Medicines and Healthcare products Regulatory Agency must not indicate or recommend their products for use on animals.’

The VMD is now contacting UK CBD suppliers and manufacturers to inform them of the decision and to ensure products containing CBD satisfy the requirements of the VMR.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.